Weekly oral alendronic acid in male osteoporosis

Clinical Drug Investigation

Volumn 24, Issue 6, 2004, Pages 333-341

  Miller, Paul D ^a   Schnitzer, Thomas ^b   Emkey, Ronald ^c   Orwoll, Eric ^d   Rosen, Clifford ^e   Ettinger, Mark ^f   Vandormael, Kristel ^g   Daifotis, Anastasia ^g  

^a University of Colorado Health Sciences Center   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Emkey Arthritis and Osteoporosis Clinic   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e ST JOSEPH HOSPITAL   (United States)

^f Regional Osteoporosis Center   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; CALCIUM; PLACEBO; VITAMIN D;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGUS DISEASE; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; OSTEOPOROSIS; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 3042745539     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424060-00003     Document Type: Article

References (23)

1. Scane AC, Sutcliffe AM, Francis RM. Osteoporosis in men. Ballieres Clin Rheumatol 1993; 7: 589-601
2. Mussolino ME, Looker AC, Madans JH, et al. Risk factors for hip fracture in White men: the NHANES I epidemiologic follow-up study. J Bone Miner Res 1998; 13; 918-24
3. Lin JH, Chen IW, deLuna FA. Nonlinear kinetics of alendronate. Plasma protein binding and bone uptake. Drug Metab Dispos 1994; 22: 400-5
4. Cranney A, Guyatt G, Griffith L, et al. Summary of metaanalyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 496-578
5. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once weekly and alendronate 10mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000; 12: 1-12
6. Greenspan SL, Bone III HG, Schnitzer TJ, et al. Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17: 1988-95
7. Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70mg versus once-daily alendronate 10mg: a multicenter, randomized, open-label, cross-over study. Clin Ther 2002; 24: 1871-86
8. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-10
9. Genant HK, Wu CY, Van Kuijk C, et al. Vertebral fracture assessment using a semiquantitiative technique. J Bone Miner Res 1993; 8: 1137-48
10. Carlsen CG, Soerensen TH, Eriksen EF. Prevalence of low serum estradiol levels in male osteoporosis. Osteoporos Int 2000; 11: 697-701
11. Katznelson L, Finkelstein JS, Shoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81: 4358-65
12. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966-72
13. Orwoll E. Osteoporosis in men. Endocrinol Metab Clin North Am 1998; 27: 349-67
14. Hochberg MC, Greenspan SL, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87: 1586-92
15. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85: 231-6
16. Hochberg M, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 1999; 42: 1246-54
17. Guy JA, Shea M, Peter CP, et al. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 1993; 53: 283-8
18. Bone HG, Hosking D, Devogelaer J-P, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189-99
19. Cryer B, Bauer D. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002; 77: 1031-43
20. Schuit SCE, van der Klift M, Weel AEAM, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34: 195-202
21. Eastell R, Boyle IT, Compston J, et al. Management of male osteoporosis: report of the UK Consensus Group. QJM 1998; 91: 71-92
22. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 878-82
23. Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002; 162: 2217-22